In April 2016, the Company’s Board of Directors and the convertible preferred stockholders representing a majority of the Company’s outstanding stock approved, the Monopar Therapeutics Inc. 2016 Stock Incentive Plan (the “Plan”) allowing the Company to grant up to an aggregate 700,000 shares of stock awards, stock options, stock appreciation rights and other stock-based awards to employees, directors and consultants. Concurrently, the Board of Directors granted to certain Board members and the Company’s acting chief financial officer stock options to purchase up to an aggregate 273,000 shares of the Company’s common stock at an exercise price of $0.001 par value based upon a third-party valuation of the Company’s common stock.

In December 2016, the Board of Directors granted stock options to purchase up to 7,000 shares of the Company’s common stock at an exercise price of $0.001 par value to the Company’s acting chief medical officer.

In February 2017, the Board of Directors granted to certain Board members and the Company’s acting chief financial officer stock options to purchase up to an aggregate 275,520 shares of the Company’s common stock at an exercise price of $0.001 par value based upon a third-party valuation of the Company’s common stock. In September 2017, the Board of Directors represented by the designated Plan Administrator, granted options to purchase up to 21,024 shares of common stock to each of the three new Board members at an exercise price of $6 per share based on the price per share at which common stock was sold in the Company’s most recent private offering.

Under the Plan, the per share exercise price for the shares to be issued upon exercise of an option shall be determined by the Plan administrator, except that the per share exercise price shall be no less than 100% of the fair market value per share on the grant date. Fair market value is established by the Company’s Board of Directors, using third party valuation reports and recent financings. Options generally expire after ten years.

Stock option activity under the Plan was as follows:

A summary of options outstanding as of December 31, 2017 is shown below:

During the years ended December 31, 2017 and 2016, the Company recognized $26,864 and $0 of employee and non-employee director stock-based compensation expense as general and administrative expenses, respectively, and $26,499 and $0 as research and development expenses, respectively. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements.

The Company recognizes as an expense the fair value of options granted to persons who are neither employees nor directors. The fair value of expensed options was based on the Black-Scholes option-pricing model assuming the following factors: 6.1 to 5.3 years expected term, 57% volatility, 2.2% to 1.2% risk free interest rate and zero dividends. The expected term for options granted to date is estimated using the simplified method. Stock-based compensation expense for non-employees for the years ended December 31, 2017 and 2016 was $251,842 and $0, respectively, of which $199,769 and $0, respectively was recorded as research and development expenses and $52,073 and $0, respectively, as general and administrative expenses. For the years ended December 31, 2017 and 2016: the weighted average grant date fair value was $0.88 and $0.00 per share, respectively; and the fair value of shares vested were approximately $0.3 million and nominal, respectively.  At December 31, 2017, the aggregate intrinsic value was approximately $3.3 million of which approximately $2.0 million was vested and approximately $1.3 million is expected to vest and the weighted average exercise price in aggregate was $0.94 which includes $0.001 for fully vested stock options and $1.93 for stock options expected to vest. At December 31, 2017 unamortized unvested balance of stock base compensation was $925,126, to be amortized over 3.3 years.